By now you’ve probably heard about how many Americans suffer from a heart attack.
A recent study conducted by researchers at Brigham and Women’s Hospital and Brigham and Men’s Hospital found that the average American spends nearly $1,000 on a heart-attack care visit annually.
While the costs are steep, there’s hope.
A new class of medications developed by researchers from Brigham and Young University has the potential to significantly lower your risk of developing a fatal heart attack and possibly even save your life.
“These drugs, if they’re approved, would be very important to the survival of the human race,” said Dr. Jeffrey Wills, one of the study’s authors.
“They’re going to have a profound effect on what happens to the hearts of people with heart failure.”
While the study, which is published in the American Journal of Cardiology, focused on the effects of one of several new drugs that were approved for use in the U.S. in the past year, the new research also looked at other new medications that were developed by companies to help treat the symptoms of heart failure.
They include a drug called Zaltrap, which was recently approved by the FDA for use to treat people with type 2 diabetes.
The FDA recently approved a second drug, called Nubexx, which also works to treat the effects associated with a type 2 heart failure but is also approved to treat other diseases such as Alzheimer’s disease.
While the new drugs have proven to have significant clinical trials and clinical results to date, they’re still in the early stages of development.
The new medications have a long way to go before they’re ready for patients to start using them.
“We’ve been working on this for over five years now, and we’ve been looking at these drugs for a very long time,” said Wills.
“We knew they were going to be incredibly important in helping people with these heart failures survive.”
So what are these drugs doing?
They’re helping to slow the progression of the heart disease, which can affect both the heart and blood vessels.
The drugs act as a way to stop the heart from beating too fast.
This helps stop the buildup of plaque in the heart’s arteries and block it from clogging up the blood vessels, making it harder for the heart to pump blood efficiently.
“Our understanding of how the heart works and how it responds to external stress is very different from what’s in the brains of patients who have heart failure,” said Andrew S. Wiebe, a cardiologist at Brigham’s Cardiovascular Research Institute.
“So we knew that this drug would help them with their disease and their symptoms, but we didn’t know exactly how it would help their heart.”
Using Zaltra, researchers at the Brigham and Wyeth School of Medicine have shown that Zaltracys could be used to slow progression of heart disease.
“Zaltracx works in part by reducing the plaque buildup in the arteries,” said Srinivasan.
“That allows the heart cells to continue pumping blood more efficiently.”
The drug also has an effect on other parts of the body.
When people take Zaltrols, their immune systems are able to help reduce inflammation in the blood and reduce the symptoms that can result from heart failure, said Wiebbe.
The researchers are now looking at other potential therapies that might slow progression in the same way, and are working on finding additional treatments that could slow the heart, and therefore the death rate, of heart attacks.
“There are many things that we’re doing now, but the drugs that we’ve tested so far are very exciting,” said Nucetink.
“I’m optimistic that we’ll be able to find some very promising drugs that may slow the disease progression.”
But as soon as the drugs are approved, they could have a huge impact on the lives of millions of people who are now suffering from heart attacks every day.
While some heart failure drugs have already been approved by a number of countries, many others haven’t, and it’s up to patients and their doctors to figure out which medications work best for them.
This could mean a lot of money and many lives are at stake.